Text Size

Tailor your approach—talk to your client about 2 best-in-class options for relief: CYTOPOINT® and APOQUEL®

With CYTOPOINT, a single in-office injection offers 4 to 8 weeks of relief,* giving damaged skin a chance to heal and helping to improve the quality of life for dogs and their families¹
Both APOQUEL and CYTOPOINT have distinct advantages for relieving allergic itch

For rapid relief you can start and stop

Starts providing itch relief within 4 hours²

Targets itch and inﬂammatory cytokines, resulting in signiﬁcant reduction of pruritus and inﬂammation³

Can be used long term for maintenance therapy and with many other medications, including NSAIDs, anti-infectives, parasiticides, antifungals and allergen-speciﬁc therapy²*

Allows ﬂexibility to stop and start control of pruritus quickly—as necessary—for assessments during the diagnostic workup (eg, ﬂea and food trials)

APOQUEL is a great choice for:

rapid allergic itch relief²

start-and-stop itch control

use during diagnostic tests⁵

dogs at least 12 months of age

management of pruritic flares

short- and long-term management of itch

*The use of APOQUEL has not been evaluated in combination with other systemic immunosuppressants, such as corticosteroids and cyclosporine.

For sustained, long-lasting relief

Begins to relieve itch within 24 hours and lasts for 4 to 8 weeks¹

Can be used in dogs with concomitant disease or in combination with other commonly used medications, including APOQUEL⁹

Targets and neutralizes interleukin (IL)-31, a key itch-inducing cytokine in allergic and atopic dermatitis¹⁰

Provides long-lasting relief with a single in-office injection, ensuring compliance¹

CYTOPOINT is a great choice for:

dogs who are difficult to pill or cases in which owner compliance is a concern

dogs with comorbidities

owners who seek
non-drug therapy

dogs of all ages

management of pruritic flares

dogs requiring lasting,
lifelong disease management

When treating a patient with atopic dermatitis, remember:

Treat for fleas year-round

Dogs with atopic dermatitis should be treated year-round for fleas^6†

Remain vigilant for infection

Up to 33% of dogs with atopic dermatitis have a concurrent yeast infection, and up to 66% have a concurrent bacterial skin infection⁷

Exeland's story⁸

9-year-old male Labrador Retriever
Atopic dermatitis uncontrolled with antihistamines, glucocorticoids, cyclosporine, allergen-specific immunotherapy and elimination diet
Diagnosed with blastomycosis and treated with systemic antifungals, and secondary bacterial pneumonia and Staph pyoderma treated with systemic antibiotics
Exeland's veterinarian chose CYTOPOINT to manage the atopic dermatitis
2 days after the initial injection, Exeland's owner reported that the itch was 0/10
Exeland's blastomycosis continues improving clinically and he remains free of skin and ear infections

Exeland before CYTOPOINT for his atopic dermatitis

Before Treatment
Staph pyoderma secondary to uncontrolled atopic dermatitis.

Exeland after CYTOPOINT for his atopic dermatitis

After Treatment

CYTOPOINT helped protect the bond

Exeland's owner has a debilitating condition that affects his manual dexterity and makes regular pilling challenging, and Exeland's treatments and illness had been both mentally and physically overwhelming for him. For both owner and dog, Exeland's refractory itch had a severe negative impact on quality of life before CYTOPOINT.

Next, Long-term management

Learn more at CYTOPOINT.COM

Learn more at APOQUEL.COM

CYTOPOINT INDICATIONS: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

APOQUEL INDICATIONS: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL IMPORTANT SAFETY INFORMATION: Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

Repeat administration every 4 to 8 weeks as needed in individual patients.¹

2015 ICADA Guidelines recommend systemic and oral adulticides like SIMPARICA for dogs who are frequently shampooed.

References: 1. Data on file, Study Report No. C863R-US-12-018, Zoetis Inc. 2. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (APOQUEL®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518. doi:10.1111/vde.12166. 3. Gonzales AJ, Bowman J, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317-324. doi:10.1111/jvp.12101. 4. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179. doi:10.1111/vde.12194. 5. Aleo MM, Galvan EA, Fleck JT, et al. Effects of oclacitinib and prednisolone on skin test sensitivity [abstract]. Vet Dermatol. 2013;24(3):297. 6. Olivry T, DeBoer D, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210. doi:10.1186/s12917-015-0514-6. 7. Bizikova P, Santoro D, Marsella R, et al. 32 of 41 Review: clinical and histological manifestations of canine atopic dermatitis. Vet Dermatol. 2015;26(2):79-e24. 8. Data on file, CYTOPOINT Case Studies, 2015, Zoetis Inc. 9. Data on file, Study Report No. C961R-US-13-051, Zoetis Inc. 10. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-53. doi:10.1111/j.1365-3164.2012.01098.x.

Testimonials represent individual experience only and the experiences and opinions herein may be unique to the patient and the speaker. Individual results may vary, considering the unique characteristics of the patient.

This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. NexGard is a trademark of the Boehringer Ingelheim group.
© 2021 Zoetis Services LLC. All rights reserved. ZPC-00064R4

1-888-963-8471

Mon–Fri, 8:30am–8:00pm ET

For animals. For health. For you.

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.